Physician profile
Heidi E Curtis
NPI 1578958542
$6,781.76
in general payments reported to CMS, 2019-2025
21 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $1,034 · 2023: $1,201 · 2024: $1,444 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,625 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,624.51 |
| Education | $433.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,995.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,499.50 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $834.73 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $473.04 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $391.61 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $266.09 | 2022-2025 | |
| Galderma Laboratories, L.P. | $247.50 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $199.69 | 2021-2025 | |
| Amgen INC. | $188.49 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $164.75 | 2021-2025 | Dupixent |
| Incyte Corporation | $115.71 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.05 | 2022-2024 | Arazlo, Jublia, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.15 | 2023-2024 | Cyltezo, Spevigo |
| Organon LLC | $66.05 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $48.79 | 2023-2024 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.61 | 2024-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $35.25 | 2021-2022 | |
| Genzyme Corporation | $23.16 | 2022 | |
| Convatec INC. | $17.90 | 2024 | |
| Leo Pharma INC. | $13.46 | 2021 | |
| Dermira, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.